Here's Why Bausch Health Stock Gained 14.7% in a Week
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push ...
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
Why Bausch + Lomb Rallied Today
Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company ...
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...
Eyecare company Bausch + Lomb explores sale to end messy spin-off
Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...
Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
The Financial Times5d
Private equity suitors line up for Bausch + Lomb eyecare auction
Bausch + Lomb is projected to generate nearly $860mn in adjusted earnings before interest, taxation, depreciation and ...
Bausch + Lomb Growth Prospects Bolstered by Strong Miebo Performance and Optimistic Sales Forecasts
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the ...
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...
Private Equity Interest Signals Upside for Bausch + Lomb: A Buy Rating Justified
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
AOL7d
Why Bausch + Lomb Rallied Today
Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...